NYSE · RDY

Dr. Reddy's Laboratories Limited American

$11.79 -$0.01 (-0.08%) 1D Market open

Key Metrics

$9.83B
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 0.21
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    From its Jun 26 high, the share price fell 26%.

    Peak close $15.38 on Jun 26; trough close $11.38 on Jul 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%
  • Jul 22
    The stock moved -9.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 22
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$9.83B
Enterprise value
Shares outstanding832.7M
52-wk range$11.36 – $15.67
Avg volume · 20D1.2M
Net cash
Book value / share
ExchangeNYSE
About Dr. Reddy's Laboratories Limited American
IPO dateApr 11, 2001
Employees27527

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings